14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RAPP vs PVLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Rapport Therapeutics, Inc. (RAPP) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). RAPP carries a Unified Composite Score of 51.5/100 (HOLD) at $25.29 (N/M Forward P/E, -838.1% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While RAPP currently prints a higher short-term Unified Composite Score (51.5/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -838.1% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Technical & Structure Timing Caution: RAPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.6); meanwhile PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPP vs PVLA. Trailing 12-month operating profitability (RAPP -838.1% vs PVLA 0.0%) and valuation multiples (RAPP N/M vs PVLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RAPP vs PVLA Key Questions & Quantitative Answers
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Rapport Therapeutics, Inc. (RAPP) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). RAPP carries a Unified Composite Score of 51.5/100 (HOLD) at $25.29 (N/M Forward P/E, -838.1% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RAPP currently prints a higher short-term Unified Composite Score (51.5/100 HOLD vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -838.1% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: RAPP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.6); meanwhile PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RAPP and PVLA split Growth & Scale metrics: RAPP posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (N/A gross margin, -838.1% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RAPP generates $20M in USD-normalized revenue versus N/A for PVLA. In operating R&D and SG&A reinvestment, RAPP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.
RAPP screens cheaper on headline valuation multiples. RAPP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 73.4x EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPP (-33.3% ROE) versus PVLA (-63.4% ROE) capital efficiency.
In options market volatility and institutional positioning, RAPP carries 93.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.91x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.34β · 109% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.